Moleculin Biotech (MBRX)

Moleculin Biotech Stock Price & Analysis


MBRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.02 - $3.08
Previous Close$1.16
Average Volume (3M)97.72K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$12.79M
Total Debt (Recent Filing)$127.00K
P/E Ratio-1.6
Next EarningsNov 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.73
Shares Outstanding28,606,706
Standard Deviation0.19
10 Day Avg. Volume181,818
30 Day Avg. Volume97,720
P/B Ratio0.50
P/S RatioN/A
P/CF RatioN/A
P/FCF Ratio-1.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside932.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $1.02 and its highest was $3.08 in the past 12 months.
    What is Moleculin Biotech’s market cap?
    Currently, no data Available
    When is Moleculin Biotech’s upcoming earnings report date?
    Moleculin Biotech’s upcoming earnings report date is Nov 15, 2022 which is in 48 days.
      How were Moleculin Biotech’s earnings last quarter?
      Moleculin Biotech released its earnings results on Aug 15, 2022. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.253 by $0.013.
        Is Moleculin Biotech overvalued?
        According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Moleculin Biotech pay dividends?
          Moleculin Biotech does not currently pay dividends.
          What is Moleculin Biotech’s EPS estimate?
          Moleculin Biotech’s EPS estimate is -$0.28.
            How many shares outstanding does Moleculin Biotech have?
            Moleculin Biotech has 28,606,707 shares outstanding.
              What happened to Moleculin Biotech’s price movement after its last earnings report?
              Moleculin Biotech reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.253. Following the earnings report the stock price went up 11.111%.
                Which hedge fund is a major shareholder of Moleculin Biotech?
                Currently, no hedge funds are holding shares in MBRX


                Moleculin Biotech Stock Analysis

                Smart ScoreNeutral
                The Moleculin Biotech stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Moleculin Biotech

                Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

                Similar Stocks
                Price & Change
                Gilead Sciences
                Vertex Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis